AARD News
Archived Headlines
- US IPO Week Ahead: Software firm SailPoint and defense contractor Karman set to lead 8 IPO week 02/07/25
- Metabolic disease biotech Aardvark Therapeutics sets terms for $100 million IPO 02/06/25
- Sizable IPO filings reach a three-year high amid steady stream of deals 01/30/25
- US IPO Weekly Recap: Venture Global prices a pared-down IPO as more sizable deals join the pipeline 01/24/25
- Metabolic disease biotech Aardvark Therapeutics files for a $100 million IPO 01/23/25
Renaissance Capital's February IPO Market Update
Eighteen IPOs raised a combined $2.8 billion in February, well above the 10-year historical average (12 IPOs, $2.1B). Micro-caps dominated deal flow, but five issuers completed offerings of $100 million or more, led by SailPoint (SAIL), which raised $1.4...read more
Bigger Biotechs: IPO valuations have soared for drug developers over the past decade
New biotech issuers have doubled in size over the past decade.Last year, the average biotech IPO went public at a market cap of $644 million, compared to $318 million a decade earlier, for deals raising at least $20 million. The average wasn’t skewed by a ...read more
US IPO Weekly Recap: Big listings post mixed results in busy 7 IPO week
Seven IPOs and three SPACs listed this week. Seven IPOs and four SPACs submitted initial filings.Identity governance software provider SailPoint (SAIL) priced it upsized IPO at the top of the upwardly revised range to raise $1.4 billion at a $13.2 billion...read more
Metabolic disease biotech Aardvark Therapeutics prices IPO at $16, the low end of the range
Aardvark Therapeutics, a Phase 3 biotech developing novel small molecule therapies for metabolic diseases, raised $94 million by offering 5.9 million shares at $16, the low end of the range of $16 to $18.Aardvark's wholly-owned lead candidate, ARD-101...read more